MedTrace Logo

AccuLIF® PROSPECTIVE PATIENT OUTCOMES STUDY

NCT02704689 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 9

Last updated 2018-04-24

Study results available
· View outcomes & findings →

Summary

This is a post-market clinical study of the AccuLIF expandable transforaminal lumbar interbody fusion (TLIF) cage in patients requiring surgery for degenerative disc disease (DDD) with up to Grade I spondylolisthesis or retrolisthesis, at one or two levels, between L2 and S1.

Conditions

  • Degenerative Disc Disease
  • Spondylolisthesis, Grade 1
  • Retrolisthesis

Interventions

DEVICE

AccuLIF expandable TLIF cage

AccuLIF TL expandable interbody cage used with autogenous bone and/or allograft (cancellous or corticocancellous allograft chips) and supplemental fixation.

Sponsors & Collaborators

  • Stryker Spine

    lead INDUSTRY

Principal Investigators

  • Theodore Choma, MD · University of Missouri Health Care

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-06-08
Primary Completion
2017-01-19
Completion
2017-01-19

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02704689 on ClinicalTrials.gov